Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
88
Frequently Asked Questions
What is Market Cap of Lyra Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Lyra Therapeutics Inc market cap is $19.51M.
What is the 52-week high for Lyra Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Lyra Therapeutics Inc 52 week high is $6.79 as of June 07, 2024.
What is the 52-week low for Lyra Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Lyra Therapeutics Inc 52 week low is $0.3054 as of June 07, 2024.
What is Lyra Therapeutics Inc stock price today?
Lyra Therapeutics Inc stock price today is $0.32.
What was Lyra Therapeutics Inc stock price yesterday?
Lyra Therapeutics Inc stock price yesterday was $0.32.
What is the PE ratio of Lyra Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Lyra Therapeutics Inc’s P/E ratio is -0.26.
What is the Price-to-Book ratio of Lyra Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Lyra Therapeutics Inc P/B ratio is 0.2517.
What is Lyra Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Lyra Therapeutics Inc's EBITDA is -4.87.
What is the 50-day moving average of Lyra Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Lyra Therapeutics Inc 50-day moving average is $3.02.
How many employess does Lyra Therapeutics Inc has?